XML 19 R1.htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Feb. 29, 2024
Jun. 30, 2023
Document Information [Line Items]      
Document Type 10-K    
Document Annual Report true    
Current Fiscal Year End Date --12-31    
Document Period End Date Dec. 31, 2023    
Document Transition Report false    
Entity File Number 001-39630    
Entity Registrant Name MOONLAKE IMMUNOTHERAPEUTICS    
Entity Incorporation, State or Country Code E9    
Entity Tax Identification Number 98-1711963    
Entity Address, Address Line One Dorfstrasse 29    
Entity Address, Postal Zip Code 6300    
Entity Address, City or Town Zug    
Entity Address, Country CH    
City Area Code 41    
Local Phone Number 415108022    
Title of 12(b) Security Class A ordinary share, par value $0.0001 per share    
Trading Symbol MLTX    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 1,120
Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement relating to its 2024 Annual Meeting of Shareholders, to be held on or about June 5, 2024, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated. Such proxy statement will be filed with the U.S. Securities and Exchange Commission within 120 days after the end of the fiscal year to which this report relates.
    
Amendment Flag false    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Entity Central Index Key 0001821586    
Common Class A      
Document Information [Line Items]      
Entity Common Stock, Shares Outstanding   62,874,637  
Common Class C      
Document Information [Line Items]      
Entity Common Stock, Shares Outstanding   1,012,120